A Full Analysis of the Study Data with Scoring of Squamous and Glandular Ulcers is Expected to be Available in January
 
San Francisco, CA (November 14, 2016): Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today issued a summary of racing data for horses taking part in the Company’s recently completed dose determination study of the target commercial paste formulation of EquileviaTM (formerly referred to as SB-300), the Company’s drug product candidate for treatment of Equine Gastric Ulcer Syndrome (“EGUS”).  
 
EquileviaTM is a pharmaceutical formulation of a standardized botanical extract. The randomized, blinded, controlled, multisite dose determination study enrolled 121 racehorses two years of age or older. All enrolled horses were diagnosed with glandular and squamous gastric ulcers. The primary objective of the study was to select the minimally effective dose of EquileviaTM for the treatment of equine gastric ulcers in a future pivotal field study.
 
Horses on treatment with EquileviaTM had higher average winnings as a percent of purse in races during the study treatment period compared with the period in which they raced prior to the study. Horses on placebo or on the positive control (Merial’s GASTROGARD¨ product) had a reduction in their average winnings as a percent of purse during the study treatment period compared with the period in which they raced prior to the study.
 
Additionally, horses on treatment with EquileviaTM had higher average total dollar winnings in races during the study period compared with the period in which they raced prior to the study. However, ho